I guess we are all here for some reason and yes, this is the Avid Bioservices CDMO ihub board....and Avid made a contract with Oncologie and others etc for IP asset rights which were NEVER fully disclosed to all shareholders but we were told about milestones royalties etc and in 15% range for net sales
ALL involved with those contracts ..past and present are 100% direct related to this board
It is fact DARPA and MANY others have been involved and Merck and many others try oh so hard to contain the info
I will say, some here that can't see it or know it...have not followed all roads to PS Targeting because the amount of information, important information ...is information overload upon some that can't follow all paths
If one is an investor in CDMO and knows we have potential...astronomical potential..
One could ask Levi Garraway or Jennifer Wipf or others Ginkgo Bioworks or Bill Gates : )
PS Targeting is HUGE and it is FACT PS Targeting IP assets / Biomarker data etc with Ginkgo Bioworks affiliates and Lockheed Martin
Let me say this....ANYTHING from stressed cells to inflammation to cancer etc has flipped PS ....I posted an interview with Laura Benjamin CEO of Oncologie that also knows well
So any atom thick brain cell knows flipped PS must be targeted and to extract the impure substance from blood will require a license to Avid Bioservices CDMO
Information Overload is what new comers will see .....and by following all paths...then one will see my posts are 100% relevant to Avid Bioservices CDMO
Those cytokine storms are not welcome in any FDA future approval and maybe Bruce Artim now with Omeros...I mean now with Eli Lilly will tell you when he is allowed to. I work for no one and have signed no non disclosures unlike many others.
Svetlana Monakhova BACHMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
GRAPHENE-BASED FILTER FOR ISOLATING A SUBSTANCE FROM BLOOD Publication number: 20170128891 Abstract: A device isolates a substance from blood. The substance includes particles with an effective diameter that is within a range defined by effective diameters of constituents of blood. The device comprises a first sheet of graphene including a first plurality of apertures. The first plurality of apertures are configured to pass objects with an effective diameter less than or equal to the effective diameter of the particles of the substance. The device comprises a second sheet of graphene including a second plurality of apertures. The second plurality of apertures are configured to pass objects with an effective diameter less than the effective diameter of the particles of the substance. The device may be configured to include a conduit system. The device may be configured to operate according to a reversible cycle.
Type: Application Filed: January 19, 2017 Publication date: May 11, 2017 Applicant: Lockheed Martin Corporation Inventors: Svetlana Monakhova Bachmann, Paul Declan Mountcastle, Byron W. Tietjen
.... ....
Graphene-based filter for isolating a substance from blood Patent number: 9572918 Abstract: A device isolates a substance from blood. The substance includes particles with an effective diameter that is within a range defined by effective diameters of constituents of blood. The device comprises a first sheet of graphene including a first plurality of apertures. The first plurality of apertures are configured to pass objects with an effective diameter less than or equal to the effective diameter of the particles of the substance. The device comprises a second sheet of graphene including a second plurality of apertures. The second plurality of apertures are configured to pass objects with an effective diameter less than the effective diameter of the particles of the substance. The device may be configured to include a conduit system. The device may be configured to operate according to a reversible cycle. Type: Grant Filed: June 21, 2013 Date of Patent: February 21, 2017 Assignee: LOCKHEED MARTIN CORPORATION Inventors: Svetlana Monakhova Bachmann, Paul Declan Mountcastle, Byron W. Tietjen
... ...
GRAPHENE-BASED FILTER FOR ISOLATING A SUBSTANCE FROM BLOOD Publication number: 20140377738 Abstract: A device isolates a substance from blood. The substance includes particles with an effective diameter that is within a range defined by effective diameters of constituents of blood. The device comprises a first sheet of graphene including a first plurality of apertures. The first plurality of apertures are configured to pass objects with an effective diameter less than or equal to the effective diameter of the particles of the substance. The device comprises a second sheet of graphene including a second plurality of apertures. The second plurality of apertures are configured to pass objects with an effective diameter less than the effective diameter of the particles of the substance. The device may be configured to include a conduit system. The device may be configured to operate according to a reversible cycle. Type: Application Filed: June 21, 2013 Publication date: December 25, 2014 Inventors: Svetlana Monakhova BACHMANN, Paul Declan MOUNTCASTLE, Byron W. TIETJEN
_______
Lockheed Martin collaborates with Ginkgo Bioworks _____
This maturation requires collaboration between ARL and Lockheed Martin and leverages commercial advances from companies such as Ginkgo Bioworks.
Lockheed Martin is Reprogramming Cells to Bioproduce New Materials $10 Million Army Research Contract Advances Precision Biodesign
NEWS PROVIDED BY Lockheed Martin Feb 26, 2019, 11:04 ET PALO ALTO, Calif., Feb. 26, 2019 /PRNewswire/ -- Cells form the cornerstone of life, and Lockheed Martin (NYSE: LMT) is researching ways to create the building blocks of novel materials. In a new cooperative agreement with the Army Research Laboratory, Lockheed Martin material scientists will work with industry and Army scientists who design microbes to edit single-cell organism DNA. They will investigate a range of capabilities, particularly those that can improve defense optical technology and coatings.
"Cells efficiently create all sorts of materials, like a spider's silk or a butterfly's iridescent wings. We want to harness nature's process to better protect people," said Melissa Rhoads, senior research manager and Lockheed Martin lead for the project. "Biodesign exists today, but it doesn't exist at the scale and to the quality of defense standards."
Biology and technology intersect in the field of biodesign. Some fashion houses even use the sustainable technology to develop fabrics for clothing, but Lockheed Martin sees potential to mature the science to a more precise level. This maturation requires collaboration between ARL and Lockheed Martin and leverages commercial advances from companies such as Ginkgo Bioworks.
Scientists often look to nature to provide inspiration, and those ideas can help lower the cost of optical technologies. For example, telescopes use lenses to filter out unwanted light or to get a clearer image. However, a squid lens is able to filter and focus light in compact package due to molecule-based design and varied refractive index. In another example, melanin protects humans and animals alike from the Sun's UV rays. So melaninâ??or similar molecules with protective functionsâ??could be another natural substance attracting the study's attention.
"We can't manufacture that kind of capability, so Lockheed Martin will try nature's way," Rhoads said. "Harnessing the power of self-assembling materials is sustainable, affordable and can be much faster to produce than artificial methods. As much potential there is for biodesign, the maturity of the materials technology is still low, so our five-year study will advance this field significantly for precision science."
The $10 million, five-year agreement uses the name Self-Assembly of Nanostructures for Tunable Materials and will leverage the Army's Open Campus model to enable collaboration between university, small-business, Army and Lockheed Martin scientists and engineers. Partnerships across industry and government groups have grown from programs like the National Science Foundation's SynBERC and the Department of Defense's Applied Research for Advancement of Science and Technology Priorities.
About Lockheed Martin
Headquartered in Bethesda, Maryland, Lockheed Martin is a global security and aerospace company that employs approximately 105,000 people worldwide and is principally engaged in the research, design, development, manufacture, integration and sustainment of advanced technology systems, products and services.
We do not know what we do not know. It is not a dead or mute issue. If it were on a shelf that would be one thing. The fact that it is in trials with kEYTRUDA VALIDATES THAT IT MAY have life. At the very least the Bavi or BB's should be a source of Rev's back at AVID.
Let them do tonnes of trials it would be a cash cow. Pre Ronin it was a cash killer.
News 
Market Data 
Discover 
